JPWO2022239704A1 - - Google Patents
Info
- Publication number
- JPWO2022239704A1 JPWO2022239704A1 JP2023520995A JP2023520995A JPWO2022239704A1 JP WO2022239704 A1 JPWO2022239704 A1 JP WO2022239704A1 JP 2023520995 A JP2023520995 A JP 2023520995A JP 2023520995 A JP2023520995 A JP 2023520995A JP WO2022239704 A1 JPWO2022239704 A1 JP WO2022239704A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021079977 | 2021-05-10 | ||
| PCT/JP2022/019548 WO2022239704A1 (ja) | 2021-05-10 | 2022-05-06 | 抗体組成物の精製方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2022239704A1 true JPWO2022239704A1 (https=) | 2022-11-17 |
| JPWO2022239704A5 JPWO2022239704A5 (https=) | 2025-05-12 |
Family
ID=84029593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023520995A Pending JPWO2022239704A1 (https=) | 2021-05-10 | 2022-05-06 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240383945A1 (https=) |
| EP (1) | EP4353734A4 (https=) |
| JP (1) | JPWO2022239704A1 (https=) |
| KR (1) | KR20240005771A (https=) |
| CN (1) | CN117279929A (https=) |
| AU (1) | AU2022271741A1 (https=) |
| CA (1) | CA3219950A1 (https=) |
| IL (1) | IL308169A (https=) |
| TW (1) | TW202309062A (https=) |
| WO (1) | WO2022239704A1 (https=) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS644947A (en) | 1987-06-29 | 1989-01-10 | Rohm Co Ltd | Consecutive recording method for video tape recorder |
| CZ299516B6 (cs) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| EP1739089A4 (en) | 2004-03-30 | 2007-05-02 | Hiroshi Yanagisawa | PROCESS FOR DISINTER SEPARATION |
| WO2008120801A1 (ja) | 2007-04-02 | 2008-10-09 | Kyowa Hakko Kirin Co., Ltd. | アンチトロンビン組成物の製造方法 |
| US9249182B2 (en) * | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
| ES2665341T3 (es) * | 2012-10-03 | 2018-04-25 | Chiome Bioscience Inc. | Anticuerpo anti-DLK-1 humana con actividad antitumoral in vivo |
| WO2014145744A1 (en) * | 2013-03-15 | 2014-09-18 | Alder Biopharmaceuticals, Inc. | Antibody purification and purity monitoring |
| US20180327447A1 (en) * | 2015-11-18 | 2018-11-15 | Merck Patent Gmbh | Improved protein separation in ion exchange chromatography |
| CA3127174A1 (en) * | 2019-01-23 | 2020-07-30 | Daiichi Sankyo Company, Limited | Methods for purifying antibodies comprising of a process by using activated carbon materials |
| US20220177582A1 (en) * | 2019-03-13 | 2022-06-09 | Ichnos Sciences SA | Non-consensus glycosylation of bispecific antibodies |
| JP2021079977A (ja) | 2019-11-19 | 2021-05-27 | 凸版印刷株式会社 | 袋状容器の注出口ユニット |
-
2022
- 2022-05-06 JP JP2023520995A patent/JPWO2022239704A1/ja active Pending
- 2022-05-06 CA CA3219950A patent/CA3219950A1/en active Pending
- 2022-05-06 IL IL308169A patent/IL308169A/en unknown
- 2022-05-06 TW TW111117152A patent/TW202309062A/zh unknown
- 2022-05-06 KR KR1020237040492A patent/KR20240005771A/ko active Pending
- 2022-05-06 EP EP22807406.8A patent/EP4353734A4/en active Pending
- 2022-05-06 US US18/289,914 patent/US20240383945A1/en active Pending
- 2022-05-06 CN CN202280033860.8A patent/CN117279929A/zh active Pending
- 2022-05-06 WO PCT/JP2022/019548 patent/WO2022239704A1/ja not_active Ceased
- 2022-05-06 AU AU2022271741A patent/AU2022271741A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117279929A (zh) | 2023-12-22 |
| CA3219950A1 (en) | 2022-11-17 |
| WO2022239704A1 (ja) | 2022-11-17 |
| TW202309062A (zh) | 2023-03-01 |
| EP4353734A1 (en) | 2024-04-17 |
| AU2022271741A1 (en) | 2023-11-23 |
| EP4353734A4 (en) | 2025-05-21 |
| IL308169A (en) | 2024-01-01 |
| KR20240005771A (ko) | 2024-01-12 |
| US20240383945A1 (en) | 2024-11-21 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250430 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250430 |